Cost Plus Drugs began selling TheracosBio’s Brenzavvy (bexagliflozin), an FDA-approved Type 2 diabetes medication, on July 13, according to a news release. Its other branded drugs are IBSA Pharma’s Tirosint; Johnson & Johnson’s Invokana, Invokamet and Invokamet extended-release; and Pfizer’s Duavee, Estring, Premarin, Premphase and Prempro.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.